Urate-lowering therapy: Uricosurics

Gout

Volumn , Issue , 2013, Pages 174-189

  Day, Richard O ^a   Williams, Kenneth M ^b   Graham, Garry G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84937413674     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.13.104     Document Type: Chapter

References (26)

1. Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 64(10), 1431-1446 (2012).
2. Enomoto A, Kimura H, Chairoungdua A et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417(6887), 447-452 (2002).
3. Vitart V, Rudan I, Hayward C et al. SCL2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 40(4), 437-442 (2008).
4. Jutabha P, Anzai N, Kitamura K et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J. Biol. Chem. 285(45), 35123-35132 (2010).
5. Woodward OM, Köttgen A, Coresh J et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl Acad. Sci. 106(25), 10338-10342 (2009).
6. Ichida K, Matsuo H, Takada T et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 3, 764 (2012).
7. Terkeltaub RA. Clinical practice. Gout. N. Engl. J. Med. 349, 1647-1655 (2003).
8. Lang F, Greger R, Oberleithner H et al. Renal handling of urate in healthy man in hyperuricaemia and renal insufficiency: circadian fluctuation, effect of water diuresis and of uricosuric agents. Eur. J. Clin. Invest. 10, 285-592 (1980).
9. Pérez-Ruiz F, Clabozo M, Fernandez-Lopez M, et al. Treatment of chronic gout in patients with renal function impairment. J. Clin. Rheumatol. 5, 49-55 (1999).
10. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of- the-art. Drugs 64, 2399-2416 (2004).
11. Perez-Ruiz F, Hernandez- Baldion S, Herrero-Beites A et al. Risk factors associated with renal lithiasis during uricosuric treatment and hyperuricemia in patients with gout. Arthritis Care Res. 62(9), 1299-1305 (2010).
12. Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J. Rheumatol. 18(4), 609-610 (1991).
13. Bailey MJ, Dickinson RG. Acyl glucuronide reactivity in perspective: biological consequences. Chem. Biol. Interact. 145,117-137 (2003).
14. Lee MH, Graham GG, Williams KM et al. A benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interest of patients? Drug Saf. 31(8), 643-665 (2008).
15. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout Ann. Rheum. Dis. 57, 545-549 (1998).
16. Reinders MK, van Roon EN, Jansen TL et al. Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann. Rheum. Dis. 68(1), 51-56 (2009).
17. Waiter-Sack I, de Vries JX, Ittensohn A. Weber E. Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles. Eur. J. Clin. Pharmacol. 39(6), 577-581 (1990).
18. Shin HJ, Takeda M, Enomoto A et al. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology 16(2), 156-162 (2011).
19. Reinders MK, Haagsma C, Jansen TL et al. A randomized controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann. Rheum. Dis. 68(6), 892-897 (2009).
20. Stocker SL, Graham GG, McLachlan AJ et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J. Rheumatol. 38(5), 904-910 (2011).
21. Takahashi H, Sato T, Shimoyama Y et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin. Pharmacol. Ther. 66(6), 569-581 (1999).
22. Feher MD, Hepburn AL, Hogarth MB et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. J. Rheumatol. 42(2), 321-325 (2003).
23. Takahashi S, Moriwaki Y, Yamamoto T et al. Effects of combination treatment using anti-hyperuricaeic agents with fenofibrate and/or losartan on uric acid metabolism. Ann. Rheum. Dis. 62, 572-575 (2003).
24. Hatch M, Freel RW, Shahinfar S et al. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. J. Pharmacol. Exp. Ther. 276(1), 187-193 (1996).
25. Kotz J. The gout pipeline crystallizes. Nat. Rev. 11, 425-426 (2012).
26. Terkeltaub R. Novel therapies for treatment of gout and hyperuricaemia. Arthritis Res. Ther. 11(4), 236 (2009).